Liraglutide, an agonist of GLP-1R, can increase acetyl-CoA carboxylase (ACC) phosphorylation through activation of AMPK, which in turn attenuates Erastin- or RSL3-induced cellular ferroptosis in the presence of high glucose, suggesting that Liraglutide ameliorates T2DM-associated NAFLD by inhibiting ferroptosis through activation of AMPK/ACC signaling [157]. This evidence concerns the gene PRKAA1 and type 2 diabetes mellitus.